Johnson & Johnson fourth innovation center settled in Shanghai

The world's largest pharmaceutical group, Johnson & Johnson, has finally identified the company's fourth innovation center layout - Shanghai, China. And in its core product line continue to do the subtraction of the background, to be the responsibility of the Chinese region will bring what kind of variables are highly concerned about the outside world.

 

21st Century Business Herald reporter learned that Johnson & Johnson Group has been in London, the United States, Boston and Menlo Park, respectively, the establishment of an innovation center, and the fourth Shanghai Innovation Center is scheduled to officially opened by the end of October.

 

At present, frequently in the tumor and liver and lung disease out of the new drug Johnson, and Roche, Novartis, GSK (GlaxoSmithKline) and other enterprises are highly competitive. As the main company of Johnson & Johnson Pharmaceuticals, the development path of Janssen (owned subsidiary in China) is largely a reflection of the Group's core strategy. "The company's selection of new drug research and development from the original 33 basic areas of analysis and screening into 10, this move makes the company in terms of human capital and capital," said Dr. Bill Hait, head of global research and development at Yang Sen Pharmaceutical, in an interview with the 21st century economic report. Are targeted, no longer a large-scale investment in the field to find a good disease areas, to make new drugs approved and listed faster than our competitors, business team will know more about how to launch this product. And last week, Johnson recently released three quarterly data show: the company's global sales reached 18.5 billion US dollars, up 5.1%. Which pharmaceutical business income of 8.3 billion US dollars, with an increase of 18.7% of the business sector in the highlights.

 

"Big buyers" Johnson & Johnson heavy drug patent cliffs approaching and early research and development failure rate of the high, making the various pharmaceutical giants of the decision to develop new drugs become more difficult. With the Johnson & Johnson Innovation Center and the new drug layout of the continuous refinement of its resources to focus on the idea of ​​fighting also emerge. For the Shanghai Innovation Center, Johnson & Johnson said: "These cooperation is Johnson & Johnson's entire enterprise-level strategy, aims to international scientific entrepreneurs to provide first-class laboratory equipment and research experts since the Innovation Center since the opening, Johnson has set up the initial "The four centers of innovation (R & D) are not independent of each other, and there is a globally harmonized strategy for any disease area," said Bill Hait. "The four innovation (R & D) centers are not independent of each other. The results will not only serve Asia, but to the world. "But compared to other large foreign companies to give R & D center in China, the core of the" right "the precedent, Johnson seems to still tend to centralized headquarters. It is reported that, in order to balance the new drug research and development of high input, high risk pressure, Johnson & Johnson in the field of treatment and open cooperation has made radical reform. In the new drugs launched in recent years, the internal R & D from the Innovation Center accounted for about one-third of the total number of new drugs, while the R & D and R & D and R & D each accounted for another third to share the risk of failure of the new drug The Capital operation has become a "buy" Johnson & Johnson routines. "Phase II of the clinical research and development we will through the acquisition and cooperation with other company results, eliminating the need for a period of two longer period of time at the same time, through the understanding of the disease, improve the late drug conversion rate. In B-cell blood malignancy is through the acquisition of a company on the west coast of the United States, which has been related to the drug. "Capital support from the secondary market is undoubtedly the international giant new drug continued" big procurement "key. In 2013, Johnson & Johnson reelected the world's largest pharmaceutical company with a market value of $ 248.4 billion, more than $ 45 billion more than the second US Pfizer.

 

"We have screened four important areas in China, namely, lung cancer, chronic obstructive pulmonary disease, hematological malignancy and liver disease, and will push the drug to China in the future," Bill Hait said. "These areas will To do the adjustment, the disease treatment can be met after the cut may be, for AIDS HIV drug investment, the company began to narrow the resources .. "At this stage, Johnson & Johnson in the field of cancer drugs ranked fourth in the world. Prior to GSK, Novartis, Eli Lilly three drug resources in a large replacement on the field of cancer drugs, for peer counterparts, Bill Hait said the company has been continuing to pay attention. There are people in the industry believe that Johnson's earnings in this growth is the main driving force is from its advanced prostate cancer drug albitron acetate and blood cancer drug erutidine and so on. And Johnson & Johnson after the focus of the strategic attack, will face Novartis, Roche and other giants blocking. According to the latest report released by the American Association for Pharmaceutical Research and Manufacturers, there are currently 771 new drugs and vaccines in the United States in clinical development stage for the treatment and prevention of cancer. Among them, lung cancer (98), leukemia (87), lymphoma (78), breast cancer (73), skin cancer (56), ovarian cancer (48) and other areas of research and development of the most concentrated, the company accounted for Quite high Also in the recent release of three quarterly Roche, harvested 11.8 billion Swiss francs (12.5 billion) in revenue, an increase of 1.8%. And this growth was attributed to the new market of cancer drugs Perjeta and Kadcyla strong trend, the two new drug sales were up more than 100% and 227%, respectively, for the company to bring 144 million and 245 million Swiss francs.